P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 219.04 INR 1.95% Market Closed
Market Cap: 289.2B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PPLPHARMA stock under the Base Case scenario is 215.89 INR. Compared to the current market price of 219.04 INR, Piramal Pharma Ltd is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PPLPHARMA Relative Value
Base Case
215.89 INR
Overvaluation 1%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
36
vs Industry
34
Median 3Y
2.4
Median 5Y
2.4
Industry
2.4
Forward
3.1
More Details
743.2
P/E
P/E
Price to Earnings
743.2
vs History
33
vs Industry
0
Median 3Y
302.8
Median 5Y
302.8
Industry
20.5
Forward
198.4
More Details
42.5
P/OCF
P/OCF
Price to OCF
42.5
vs History
18
vs Industry
9
Median 3Y
0
Median 5Y
0
Industry
15.6
More Details
42.5
P/FCFE
P/FCFE
Price to FCFE
42.5
vs History
18
vs Industry
12
Median 3Y
0
Median 5Y
0
Industry
23.1
More Details
3.7
P/B
P/B
Price to Book Value
3.7
vs History
18
vs Industry
19
Median 3Y
2.4
Median 5Y
2.4
Industry
2
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
36
vs Industry
34
Median 3Y
2.6
Median 5Y
2.6
Industry
2.5
Forward
3.2
More Details
5.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.3
vs History
36
vs Industry
36
Median 3Y
4.3
Median 5Y
4.3
Industry
4.9
More Details
26.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
26.8
vs History
9
vs Industry
13
Median 3Y
13.1
Median 5Y
13.1
Industry
12.3
Forward
20.4
More Details
26.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
26.8
vs History
9
vs Industry
16
Median 3Y
14.2
Median 5Y
14.2
Industry
15.5
Forward
41.9
More Details
44.2
EV/OCF
EV/OCF
Enterprise Value to OCF
44.2
vs History
18
vs Industry
9
Median 3Y
0
Median 5Y
0
Industry
14.1
More Details
44.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
44.2
vs History
36
vs Industry
11
Median 3Y
0
Median 5Y
0
Industry
17.5
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
18
vs Industry
31
Median 3Y
1.6
Median 5Y
1.6
Industry
1.8
More Details

Multiples Across Competitors

PPLPHARMA Competitors Multiples
Piramal Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Piramal Pharma Ltd
NSE:PPLPHARMA
289.1B INR 3.2 743.2 26.8 26.8
US
Eli Lilly and Co
NYSE:LLY
678.2B USD 13.8 61.1 32.9 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
352.1B USD 3.9 16.1 11.8 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 19 12.6 14.3
CH
Roche Holding AG
SIX:ROG
202.4B CHF 3.3 24.5 9.2 10.8
CH
Novartis AG
SIX:NOVN
175B CHF 3.9 16.2 9.6 12.9
UK
AstraZeneca PLC
LSE:AZN
155.4B GBP 3.8 26.5 129.8 195.7
US
Merck & Co Inc
NYSE:MRK
184.9B USD 2.9 10.6 8 9.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
125.2B USD 2 15.9 7 9.8
P/E Multiple
Earnings Growth PEG
IN
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Average P/E: 103.7
743.2
260%
2.9
US
Eli Lilly and Co
NYSE:LLY
61.1
49%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.5
32%
0.8
CH
Novartis AG
SIX:NOVN
16.2
17%
1
UK
AstraZeneca PLC
LSE:AZN
26.5
36%
0.7
US
Merck & Co Inc
NYSE:MRK
10.6
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Average EV/EBITDA: 395.9
26.8
1%
26.8
US
Eli Lilly and Co
NYSE:LLY
32.9
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
11.8
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.2
6%
1.5
CH
Novartis AG
SIX:NOVN
9.6
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
129.8
9%
14.4
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7
2%
3.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Average EV/EBIT: 1 699
26.8
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
36
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.5
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
14%
1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
195.7
21%
9.3
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.8
10%
1

See Also

Summary
PPLPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
PPLPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PPLPHARMA stock valuation using valuation multiples.
Wall Street Estimates
PPLPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PPLPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.